Navigation Links
Controller's Stem Cell Agency Audit Ignores California Agency's Built-in Flaws
Date:5/12/2008

SANTA MONICA, Calif., May 12 /PRNewswire-USNewswire/ -- An audit of the state stem cell agency by California's Controller ignores fundamental flaws in Proposition 71 that created the agency, Consumer Watchdog said today.

The audit released by State Controller John Chiang found that with a relatively minor exception the California Institute for Regenerative Medicine (CIRM) complies with the requirements of Proposition 71, the initiative that created the agency, as they relate to conflict-of-interest policies, grant administration, administrative expenses and expenditures.

"The problem is that Prop 71 deliberately created an oversight board that is fraught with conflict," said John M. Simpson, director of Consumer Watchdog's Stem Cell Oversight and Accountability Project. "The board is dominated by representatives of the very institutions that will receive most of the $3 billion in research funds handed out. Controller Chiang found that CIRM is following Prop 71's rules, but those rules specifically put the foxes in charge of the chicken coop."

Find a copy of the controller's news release and audit here: http://www.sco.ca.gov/eo/pressbox/2008/05/pr08026.pdf.

The audit found that "specialist" scientists had failed to sign post-review conflict-of-interest certification forms and urged that they be required to do so. CIRM said it would follow the advice.

"Big deal," said Simpson. "Under Prop 71, none of these disclosures are open to public review. They should be."

The audit did not deal with the case of John Reed, a board member who tried to influence the awarding of a grant to his institution, The Burnham Institute for Medical Research. The state's ethic's board, The Fair Political Practices Commission, is investigating that incident at Consumer Watchdog's request. Chiang also asked the FPPC to investigate.

Besides being created with built-in conflicts of interest the 29-member board is too big to be effective, Consumer Watchdog said. The problem with the controller's audit, the nonpartisan, nonprofit group said, is that it only examined if CIRM was following Prop 71's provisions.

"We need to go beyond that and ask what's wrong with Prop 71 that must be changed," said Simpson. "We need an outside analysis by unbiased observers. A good, hard-nosed look by the Little Hoover Commission at CIRM's operations would be a good first step."

Simpson said that because all Californians are paying for Prop 71, all should benefit from it. When there are cures and treatments resulting from the $6 billion taxpayers will spend on the project, they should be affordable and accessible.

"We need a provision that allows the State Attorney General to intervene if drugs or therapies funded by the stem cell agency are priced unreasonably," said Simpson. "We've seen too many cases where companies benefit from publicly funded research and then set prices at obscene levels. They act like socialists when seeking research funding but are greedy capitalists when there are profits on the table."

Proposition 71 that created CIRM provides that the act can be amended three years after the initiative was passed. Amendments require a super-majority of 70 percent. The initiative passed by 59 percent of Californians in 2004. Consumer Watchdog's Stem Cell Oversight and Accountability Project is working to ensure that California's landmark stem cell research program offers accessible and affordable cures and treatments to the taxpayers who have funded it. The program will sell $3 billion in bonds over a decade to fund stem cell research. Financing charges mean the project, the largest source of stem cell research funding in the world, will cost California taxpayers $6 billion.

Consumer Watchdog is California's leading nonprofit and nonpartisan consumer watchdog group. For more information visit us on the web at: http://www.ConsumerWatchdog.org.


'/>"/>
SOURCE Consumer Watchdog
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. European Regulatory Agency Supports OPAXIO(TM) Brand Name for Cell Therapeutics Lung Cancer Drug
2. Biopure Announces Date to Meet with UKs Medicines and Healthcare Products Agency
3. Biopure Completes U.K. Regulatory Agency Inspection
4. Lambert, Edwards & Associates Named Agency of Record for The West Michigan Science & Technology Initiative
5. Ketchum Joins Forces with Clinical Trial Recruitment Agency MMG
6. Crisis Management PR Firms Advice to Stem Cell Agency Laundered Through Law Firm to Avoid Scrutiny
7. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
8. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
9. Stem Cell Agency Finally Reveals Institutions Involved in Conflict Problem
10. Sequella Lead Drug Compound SQ109 Receives Orphan Drug Status From the US FDA and Orphan Medicinal Product Designation From the European Medicines Agency for the Treatment of Tuberculosis
11. International Atomic Energy Agency and National Foundation for Cancer Research Launch Major Initiative to Improve Cancer Prevention and Treatments in Developing Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... of Prussia, PA (PRWEB) , ... February 09, 2016 , ... ... Business Development, Europe. Based in Paris, he will focus on acquiring new accounts ... are being met. , “Fred brings to our European clients more ...
(Date:2/9/2016)... Feb. 9, 2016  DNAtrix, a clinical ... cancer, announced that its lead product, DNX-2401, ... as an orphan medicinal product for the ... of glioma, strikes approximately 25,000 people a ... http://photos.prnewswire.com/prnh/20160208/330986LOGO --> ...
(Date:2/9/2016)... 2016 BERG, a biopharmaceutical company uncovering ... has announced the appointment of Jason Haddock ... Officer. Haddock brings to BERG over 20 years ... in senior financial functions at pharmaceutical companies, as ... management. Niven R. Narain , ...
(Date:2/8/2016)... , Feb. 8, 2016  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced that it ... agreement with Hercules Technology Growth Capital, Inc. and ... million in financing. --> ... $25 million of financing under the loan and ...
Breaking Biology Technology:
(Date:2/3/2016)... , February 4, 2016 --> ... SEK 1,351.5 M (105.0), up 1,187% compared with fourth quarter of 2014. ... to SEK 517.6 M (loss: 30.0). Earnings per share increased ... was SEK 537.4 M (neg: 74.7). , ... Revenues amounted to SEK 2,900.5 M (233.6), up 1,142% compared with 2014. ...
(Date:2/2/2016)... , Feb. 2, 2016 This BCC ... bioinformatic market by reviewing the recent advances in ... that drive the field forward. Includes forecast through ... Identify the challenges and opportunities that exist in ... software solution developers, as well as IT and ...
(Date:2/1/2016)... -- Rising sales of consumer electronics coupled ... gesture control market size through ... electronics coupled with new technological advancements to drive global ... through 2020   --> Rising ... to drive global touchfree intuitive gesture control market ...
Breaking Biology News(10 mins):